Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: A prospective study

Human Reproduction

Volumn 14, Issue 2, 1999, Pages 479-484

  Grimbizis, Grigoris ^a   Tsalikis, Tryfon ^a   Tzioufa, Valentini ^a   Kasapis, Michalis ^a   Mantalenakis, Sergios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Endometrial hyperplasia; Gonadotrophin releasing hormone analogues; Menorrhagia; Uterine bleeding

Indexed keywords

GONADORELIN; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CURETTAGE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PROGNOSIS; REMISSION; RISK FACTOR; UTERUS BLEEDING;

EID: 0033012639     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/14.2.479     Document Type: Article

References (51)

1. Affinito, P., Di Carlo, C., Di Mauro, P. et al. (1994) Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. Maturitas, 20, 191-198.
2. Agorastos, T., Bontis, J., Vakiani, A. et al. (1997) Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric and DNA-cytometric data. Gynecol. Oncol., 65, 102-114.
3. Bai, M.K., Costopoulos, J.S., Christoforidou, B.P. and Papadimitriou, C.S. (1994) Immunohistochemical detection of the c-myc oncogene product in normal, hyperplastic and carcinomatous endometrium. Oncology, 51, 314-319.
4. Bonfirraro, G., Sanna, B., De Marco, A. et al. (1995) Use of a GnRH analogue in the treatment of some forms of endometrial hyperplasia associated with menometorrhagia. Minerva Gynecol., 47, 467-470.
5. Broekmans, F.J. (1996) GnRH agonists and uterine leiomyomas. Hum. Reprod., 11 (suppl 3), 3-25.
6. Bulletti C., Jasonni V.M., Tabanelli S. et al. (1987) Danazol reverses endometrial hyperplasia to normal endometrium. Acta Eur. Fertil., 18, 185-187.
7. Busacca, M., Luchini, S., Malinari, M.A. et al. (1987) Hysteroscopic pictures following danazol therapy in endometrial hyperplasia. Acta Eur. Fertil., 18, 197-201.
8. Casper, F.R. and Chapdelaine, A. (1993) Oestrogen and interrupted progestin: a new concept for menopausal hormone replacement therapy. Am. J. Obstet. Gynecol., 168, 1188-1196.
9. Chamlian, L.D. and Taylor, B.H. (1970) Endometrial hyperplasia in young women. Obstet. Gynecol., 36, 659-666.
10. Dallenbach-Hellweg, G. (1987) Histopathology of the Endometrium, 4th edition. Springer-Verlag, Berlin.
11. De Leo, V., Morgante, G., Lanzetta, D. et al. (1997) Danazol administration after gonadotrophin-releasing hormone analogue reduces rebound of uterine myomas. Hum. Reprod., 12, 357-360.
12. De Vriese, G. and Bonte, J. (1993) Possible role of goserelin, an LH-RH agonist in the treatment of gynaecological cancers. Eur. J. Gynaecol. Oncol., 14, 187-191.
13. Eichner, E. and Abelera, M. (1971) Endometrial hyperplasia treated by progestins. Obstet. Gynecol., 38, 739-742.
14. Emons, G. and Schally, V.A. (1994) The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum. Reprod., 9, 1364-1369.
15. Emons, G., Kullander, S. and Pahwa, G.S. (1988) GnRH binding in human endometrial cancer. In Abstracts of 12th World Congress of Gynecology and Obstetrics, Rio de Janeiro, Brazil. Bandeirante S.A. Grafica et Editora. Rio de Janeiro, Brazil, p. 560.
16. Emons, G., Schroder, B., Orthmann, O. et al. (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab., 77, 1458-1464.
17. Enomoto, T., Fujita, M., Inoue, M. et al. (1993) Alterations of the p53 tumour suppressor gene and its association with activation of c-k-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res., 53, 1883-1888.
18. Ferenczy, A. and Gelfand, M.M. (1986) Hyperplasia vs neoplasia: two tracks for the endometrium. Contemp. Obstet. Gynecol., 28, 79-96
19. Ferenczy, A. and Gelfand, M.M. (1989) The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am. J. Obstet. Gynecol., 160, 126-131
20. Gal, D. (1986) Hormonal therapy for lesions of the endometrium. Semin. Oncol., 13, 33-36.
21. Gal, D., Edman, D.C., Vellios, F. and Forney J.P. (1983) Long term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am. J. Obstet. Gynecol., 146, 316-322.
22. Gallagher, C.J., Oliver, R.T., Ohram, D.H., et al. (1991) A new treatment for endometrial cancer with gonadotropin releasing-hormone analogue. Br. J. Obstet. Gynaecol., 98, 1037-1041.
23. Garosso, G., La Greca, M., Lomeo, E. and Panella, M. (1993) Goserelin treatment in glandular hyperplasia. Clin. Exp. Obstet. Gynecol., 20, 268-272.
24. Gnatuk, C.L. and Ory, S.J. (1993) Causative factors in carcinogenesis: endocrine factors. In Burghardt, E. (ed.), Surgical Gynecologic Oncology. Thieme-Verlag, Stuttgart, pp. 122-125.
25. Golan, A. (1996) GnRH analogues in the treatment of uterine fibroids. Hum. Reprod., 11 (suppl. 3), 33-41.
26. Jasonni, V.M., Naldi, S., La Marca, L. et al. (1986) Preliminary report on postmenopausal endometrial hyperplasia treatment with danazol: histological and endocrinological aspects. Cancer Detect. Prevent., 9, 331-335.
27. Kullander, S. (1992) Treatment of endometrial cancer with GnRH analogues. Recent Result Cancer Res., 124, 69-73.
28. Kurman, R.J. and Norris, H. J. (1982) Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer, 49, 2547-2559.
29. Kurman, R.J., Kaminski, P.F. and Norris, H.J. (1985) The behaviour of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer, 56, 403-412.
30. Lei, Z.M., Reshef, E. and Rao, V.Ch. (1992) The expression of human chorionic gonadotropin/lutenizing hormone receptors in human endometrial and myometrial blood vessels. J. Clin. Endocrinol. Metab., 75, 651-659.
31. Lin, J., Lei, Z.M., Lojum, S. et al. (1994) Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas. J. Clin. Endocrinol. Metab., 79, 1483-1491.
32. Lindahl, B. and Willen, P. (1994) Spontaneous endometrial hyperplasia. A 5-year follow-up of 82 patients after high-dose gestagen treatment. Anticancer Res., 14, 2831-2834.
33. Lopez de la Osa Gonsalez, E. (1994) Clinical response of abnormal endometrial growth to hormonal treatment. Ann. N. Y. Acad. Sci., 734, 306-309.
34. Marshburn, B.P., Head, R.J., MacDonald, C.P. and Casey, M.L. (1992) Culture characteristics of human endometrial glandular epithelium throughout the menstrual cycle: modulation of deoxyribonucleic acid synthesis by 17β-estradiol and methoxyprogesterone acetate. Am. J. Obstet. Gynecol., 167, 1888-1898.
35. Menozzi, G., Gozzi, M, Greci, P. et al. (1992) The use of leuprolide in endometrial glandular hyperplasia. Minerva Ginecol., 44, 383-386.
36. Perino, A., Quartararo, P., Catinella, E. et al. (1987) Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur. Fertil., 18, 137-140.
37. Pozzi, M., Castagnola, D. and Cherubini, F. (1993) Treatment of endometrial hyperplasia with goserelin depot, an LH-RH analog. Minerva Ginecol., 45, 251-254.
38. Reshef, E., Lei, Z.M., Rao, V.Ch. et al. (1990) The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes and decidua. J. Clin. Endocrinol. Metab., 70, 421-430.
39. Scarselli, G., Tantini, C., Colafranceschi, M. et al. (1988) Levonorgestrelnova-T. and precancerous lesions of the endometrium. Eur. J. Gynecol. Oncol., 9, 284-286.
40. Sedati, A., Mariani, L., Gioranazzi, A. et al. (1992) The effectiveness of danazol therapy in postmenopausal women affected by endometrial hyperplasia. Clin. Exp. Obstet. Gynecol., 19, 161-165.
41. Shaw, R.W. (1996) Blood flow changes in the uterus induced by treatment with GnRH analogues. Hum. Reprod., 11 (suppl. 3), 27-32.
42. Silverberg, S.G. and Kurman, R.J. (1992) Tumours of the Uterine Corpus and Gestational Trophoblastic Disease. Armed Forces Institute of Pathology, Washington D.C.
43. Soh, E. and Sato, K. (1990) Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer, 66, 983-988.
44. Srkalovic, G., Wittliff, J.L. and Schally, A.V. (1990) Detection and partial characterization of receptors for (D-Trp-6)-luteinizing hormone releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res., 50, 1841-1846.
45. Terakawa, N., Inoue, M., Shimizu, I. et al. (1988) Preliminary report on the use of danazol in the treatment of endometrial adenomatous hyperplasia. Cancer, 62, 2618-2621.
46. Vitale, G., Linciano, M., Salamanca, S. and Ferrari, P. (1994) Anomalous uterine bleeding in perimenopause: fibromatosis, hyperplastic endometriopathy and GnRH analogues. Minerva Gynecol., 46, 317-320.
47. Volpe, A., Botticelli, A., Abrate, M. et al. (1982) An intrauterine progesterone contraceptive system (52 mg) used in pre-and peri-menopausal patients with endometrial hyperplasia. Maturitas, 4, 73-79.
48. Wall, A.J., Franklin, R.R., Kaufman, H.R. and Kaplan, L.A. (1965) The effects of clomiphene citrate on the endometrium. Am. J. Obstet. Gynecol., 93, 842-849.
49. Wentz, W.B. (1974) Progestin therapy in endometrial hyperplasia. Gynecol. Oncol., 2, 362-367.
50. Wentz, W.B. (1985) Progestin therapy in lesions of the endometrium. Semin. Oncol., 12, 23-27
51. Zagni, R., Cortelazzi, R., Cipolla, L. et al. (1993) Therapy of simple endometrial hyperplasia with GnRH analogs. Evaluation of a multicentric ambulatory study. Preliminary results. Minerva Ginecol., 45, 597-602.